| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P819 | ADS bibcode | 2013PLoSO...858287S |
| P356 | DOI | 10.1371/JOURNAL.PONE.0058287 |
| P8608 | Fatcat ID | release_63uxfeaicjg33cqlf4t3cuqypi |
| P932 | PMC publication ID | 3589263 |
| P698 | PubMed publication ID | 23472172 |
| P5875 | ResearchGate publication ID | 235886455 |
| P50 | author | Giuseppe Rengo | Q38137116 |
| Dario Leosco | Q38321641 | ||
| Bruno Trimarco | Q38321707 | ||
| Gianluigi Savarese | Q43125824 | ||
| P2093 | author name string | Pasquale Perrone-Filardi | |
| Santo Dellegrottaglie | |||
| Maria Prastaro | |||
| Francesco Gambardella | |||
| P2860 | cites work | Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT‐proBNP Guided Management of Heart Failure – SIGNAL‐HF (Swedish Intervention study – Guidelines and NT‐proBNP AnaLysis in Heart Failure) | Q51654594 |
| Explaining heterogeneity in meta-analysis: a comparison of methods. | Q52141807 | ||
| Incorporating variations in the quality of individual randomized trials into meta-analysis. | Q52861603 | ||
| More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure | Q57396381 | ||
| Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis | Q57618829 | ||
| Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension? | Q57618842 | ||
| Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients | Q60630346 | ||
| Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations | Q73736775 | ||
| [Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure] | Q84623455 | ||
| 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration | Q22306346 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 | ||
| Comparison of two methods to detect publication bias in meta-analysis | Q29617904 | ||
| Self-management counseling in patients with heart failure: the heart failure adherence and retention randomized behavioral trial | Q33898035 | ||
| Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. | Q34510811 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the | Q34640762 | ||
| Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population | Q35582125 | ||
| BNP or NTproBNP? A clinician's perspective. | Q37124035 | ||
| Biomarker guided therapy for heart failure: focus on natriuretic peptides | Q37450908 | ||
| Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials | Q37584696 | ||
| Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care | Q37762320 | ||
| Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure | Q37801830 | ||
| BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial | Q38383948 | ||
| Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome | Q39734086 | ||
| Heart failure-related hospitalization in the U.S., 1979 to 2004. | Q40064105 | ||
| When can odds ratios mislead? | Q41742782 | ||
| Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality | Q42781665 | ||
| N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study | Q43156281 | ||
| N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial | Q43549494 | ||
| Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). | Q43825224 | ||
| Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial | Q45069603 | ||
| Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Stu | Q46034385 | ||
| Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker | Q46082168 | ||
| Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey | Q46435130 | ||
| BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure | Q46757865 | ||
| Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study | Q48194485 | ||
| B-type natriuretic peptide-guided heart failure therapy: A meta-analysis | Q48263615 | ||
| Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker | Q48358493 | ||
| Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction | Q48469388 | ||
| Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction | Q48563810 | ||
| The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure | Q48971321 | ||
| N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction | Q49153716 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic heart failure | Q11829287 |
| heart failure | Q181754 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | e58287 | |
| P577 | publication date | 2013-03-05 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials | |
| P478 | volume | 8 |
| Q35755817 | 1,25-Dihydroxyvitamin D to PTH(1-84) Ratios Strongly Predict Cardiovascular Death in Heart Failure |
| Q37171880 | A review on B-type natriuretic peptide monitoring: assays and biosensors |
| Q41083010 | ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. |
| Q35017888 | Aerobic exercise effect on prognostic markers for systolic heart failure patients: a systematic review and meta-analysis |
| Q41239335 | Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure |
| Q48377696 | B-type natriuretic peptide-guided risk assessment for postoperative complications in lung cancer surgery |
| Q59767864 | B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data |
| Q38235223 | B-type natriuretic peptide-guided therapy: a systematic review |
| Q30238936 | B-type natriuretic peptide-guided treatment for heart failure. |
| Q88711582 | Biomarker Guided Therapy in Chronic Heart Failure |
| Q44566168 | Brain natriuretic peptide-guided management of chronic heart failure: first do no harm |
| Q28081433 | Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use |
| Q38967512 | Can Natriuretic Peptides be Used to Guide Therapy? |
| Q41534613 | Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels? |
| Q34324812 | Charting a roadmap for heart failure biomarker studies |
| Q38096829 | Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin |
| Q35179984 | Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials |
| Q50890696 | Dynamic Changes in High-Sensitivity Cardiac Troponin I Are Associated with Dynamic Changes in Sum Absolute QRST Integral on Surface Electrocardiogram in Acute Decompensated Heart Failure. |
| Q27012693 | Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis |
| Q58738210 | Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease |
| Q37594289 | Effects of exercise on cardiovascular performance in the elderly |
| Q38172127 | Effects of exercise training on cardiovascular adrenergic system |
| Q57705901 | Essential components in natriuretic peptide-guided management of heart failure: an intervention synthesis |
| Q38680570 | Galectin-3 correlates with arrhythmogenic right ventricular cardiomyopathy and predicts the risk of ventricular -arrhythmias in patients with implantable defibrillators |
| Q37681401 | Heart failure in patients presenting with dyspnoea to the emergency department in the Asia Pacific region: an observational study |
| Q48003695 | Heart failure readmissions. |
| Q27339180 | Hypothyroidism and its rapid correction alter cardiac remodeling |
| Q51376676 | Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function. |
| Q42646632 | In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment. |
| Q34250674 | Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients |
| Q38378152 | NT-proBNP and Echocardiographic Parameters for Prediction of Cardiovascular Outcomes in Patients with CKD Stages G2-G4. |
| Q48582357 | Natriuretic peptide levels taken following unplanned admission to a cardiology department predict the duration of hospitalization |
| Q38161695 | Natriuretic peptide-guided heart failure management |
| Q92050728 | Natriuretic peptide-guided treatment for heart failure: a systematic review and meta-analysis |
| Q90717399 | Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure |
| Q38162429 | Natriuretic peptides in cardiovascular diseases: current use and perspectives |
| Q37404953 | Neuro-hormonal effects of physical activity in the elderly |
| Q64883707 | Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2. |
| Q38114009 | Old and new tools to assess dyspnea in the hospitalized patient |
| Q47596916 | Pharmacogenomics of the Natriuretic Peptide System in Heart Failure |
| Q38424871 | Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure |
| Q38471023 | Prognostic value of galectin-3 in patients with heart failure |
| Q33960469 | Protocol for a systematic review and individual participant data meta-analysis of B-type natriuretic peptide-guided therapy for heart failure. |
| Q34324771 | Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure |
| Q48217947 | Saliva and plasma levels of cardiac-related biomarkers in post-myocardial infarction patients |
| Q55088794 | Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis. |
| Q38546917 | Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014). |
| Q44540336 | The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent Heart Failure and Death in Patients with Stable Coronary Artery Disease: The Heart and Soul Study |
| Q87844785 | The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study |
| Q35673626 | The human cardiac and skeletal muscle proteomes defined by transcriptomics and antibody-based profiling |
| Q38551693 | The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management |
| Q30434020 | The potential value of integrated natriuretic peptide and echo-guided heart failure management |
| Q26851767 | Treatment goals of pulmonary hypertension |
| Q60928393 | Update on heart failure management and future directions |
| Q35792547 | Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials |
Search more.